Chlamydia pneumoniae and Atherosclerosis: Animal Models

  • L. A. Campbell
  • C.-C. Kuo


The cumulative seroepidemiologic studies, direct detection of Chlamydia pneumoniae antigen in atherosclerotic lesions throughout the arterial tree, and culturing of the organism from atheromatous tissue provide compelling evidence for an association of C. pneumoniae with atherosclerosis [1]. However, these findings do not establish causality, which can only be proven through the use of animal models or intervention studies. This chapter will focus on animal models of C. pneumoniae and their use in studying pathogenesis, intervention strategies for eradication of acute and chronic infection, and putative roles of C. pneumoniae infection on atherogenesis. The recent establishment of mouse and rabbit models of C. pneumoniae infection that also are well-defined experimental models of atherosclerosis has provided the opportunity to address the hypothesis that C. pneumoniae infection affects the onset, severity, or progression of atherosclerosis.


Atherosclerotic Lesion Nonhuman Primate Rabbit Model Post Inoculation Single Inoculation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grayston JT, Kuo C-C, Campbell LA, Wang S-P, Jackson L (1997) Chlamydia pneumoniae and cardiovascular disease. Cardiologia 42: 1145–1151PubMedGoogle Scholar
  2. 2.
    Yang Z-P, Kuo C-C, Grayston JT (1993) A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis. Infect Immun 61: 2037–2040PubMedGoogle Scholar
  3. 3.
    Kaukoranta-Tolvanen SS, Laurila AL, Saikku P, Leinonen M, Liesirova L, Laitinen K (1993) Experimental infection of Chlamydia pneumoniae in mice. Microb Pathog 15: 293–302PubMedCrossRefGoogle Scholar
  4. 4.
    Yang Z-P, Cummings PK, Patton DL, Kuo C-C (1995) Ultrastructural lung pathology of experimental Chlamydia pneumoniae pneumonitis in mice. J Infect Dis 171: 736–738PubMedCrossRefGoogle Scholar
  5. 5.
    Moazed TC, Kuo C-C, Grayston JT, Campbell LA (1996) An experimental rabbit model of Chlamydia pneumoniae infection. Am J Pathol 148: 667–676PubMedGoogle Scholar
  6. 6.
    Bell TA, Kuo C-C, Wang S-P, Grayston JT (1989) Experimental infection of baboons (Papio cynocephalus anubis) with Chlamydia pneumoniae strain “TWAR.” J Infect 29: 47–49CrossRefGoogle Scholar
  7. 7.
    Holland SM, Taylor HR, Gaydos CA, Kappus EW, Quinn TC (1990) Experimental infection with Chlamydia pneumoniae in nonhuman primates. Infect Immun 58: 593–597PubMedGoogle Scholar
  8. 8.
    Moazed TC, Kuo C-C, Grayston JT, Campbell LA (1997) Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 175: 883–890PubMedCrossRefGoogle Scholar
  9. 9.
    Malinverni R, Kuo C-C, Campbell LA, Grayston JT (1995) Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. J Infect Dis 172: 593–594PubMedCrossRefGoogle Scholar
  10. 10.
    Yang Z-P, Kuo C-C, Grayston JT (1995) Systemic dissemination of Chlamydia pneumoniae following intranasal inoculation in mice. J Infect Dis 171: 736–738PubMedCrossRefGoogle Scholar
  11. 11.
    Moazed TC, Kuo C-C, Grayston JT, Campbell LA (1998) Systemic dissemination of C. pneumoniae infection via macrophages. J Infect Dis 177: 1322–1325PubMedCrossRefGoogle Scholar
  12. 12.
    Jackson LA, Campbell LA, Schmidt RA, Kuo C-C, Cappuccio AL, Grayston JT (1997) Specificity of detection of Chlamydia pneumoniae in cardiovascular and non-cardiovascular tissues: evaluation of the innocent bystander hypothesis. Am J Pathol 150: 1785–1790PubMedGoogle Scholar
  13. 13.
    Boman J, Söderberg S, Forsberg J, Birgander LS, Allard A, Persson K, Jidell E, Kumlin U, Juto P, Waldenström A, Wadell G (1998) High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease in middle-aged blood donors. J Infect Dis 178: 274–277PubMedCrossRefGoogle Scholar
  14. 14.
    Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo C-C (1998) Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apoE-deficient mice. In: Stephens RS, Byrne GI, Christiansen G, Clark I, Grayston JT, Hatch T, Ridgeway G, Saikku P, Schachter J, Stamm WE (eds) Chlamydial infections. University of California Printing Services, Berkeley, pp 426–429Google Scholar
  15. 15.
    Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N (1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 189: 4471–4475CrossRefGoogle Scholar
  16. 16.
    Reddick RL, Zhang SH, Maeda N (1994) Atherosclerosis in mice lacking Apo E. Evaluation of lesional development and progression. Atheroscler Thromb 14: 141–147CrossRefGoogle Scholar
  17. 17.
    Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis. Atheroscler Thromb 14: 133–140CrossRefGoogle Scholar
  18. 18.
    Grönhagen-Riska C, Saikku P, Riska H, Froseth B, Grayston JT (1988) Antibodies to TWAR-a novel type of Chlamydia — in sarcoidosis. In: Grassi C, Rizzato G, Pozzi E (eds) Sarcoidosis and other granulomatous disorders. Excerpta Medica, Amsterdam, pp 297–301Google Scholar
  19. 19.
    Danesh J, Collins R, Peto R (1997) Chronic infections and coronary heart disease: is there a link? Lancet 350: 430–436PubMedCrossRefGoogle Scholar
  20. 20.
    Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J (1997) Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 35: 48–52PubMedGoogle Scholar
  21. 21.
    Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P (1997) Chlamydia pneumoniaeinfection induces inflammatory changes in the aortas of rabbits. Infect Immun 65: 4832–4835PubMedGoogle Scholar
  22. 22.
    Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF (1998) Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97: 633–636PubMedGoogle Scholar
  23. 23.
    Laitinen K, Laurila AL, Leinonen M, Saikku P (1996) Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. Infect Immun 64: 1488–1490PubMedGoogle Scholar
  24. 24.
    Malinverni R, Kuo C-C, Campbell LA, Lee A, Grayston JT (1995) Chlamydia pneumoniae (TWAR) pneumonitis: effect of two antibiotic regimens on the course and persistence of infection. Antimicrob Agents Chemother 39: 45–49PubMedGoogle Scholar
  25. 25.
    Masson MD, Toseland CDN, Beale AS (1995) Relevance of Chlamydia pneumoniaemurine pneumonitis model to evaluation of antimicrobial agents. Antimicrob Agents Chemother 39: 1959–1964PubMedGoogle Scholar
  26. 26.
    Campbell LA, Moazed TC, Kuo C-C, Grayston JT (1997) Preclinical models for Chlamydia pneumoniae and cardiovascular disease-hypercholesterolemic mice. Presented at Hoechst Marion Roussel. Roundtable on new concepts in the role of intracellular pathogens in chronic diseases. Sydney, Australia, July 2, 1997Google Scholar

Copyright information

© Springer-Verlag Italia, Milano 1999

Authors and Affiliations

  • L. A. Campbell
  • C.-C. Kuo

There are no affiliations available

Personalised recommendations